Imageable Brachytherapy with Chelator‐Free Radiolabeling Hydrogel
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Zhencun Cui und 12 weiteren Autor:innen. Beteiligte Einrichtung: MOE Frontiers Science Center for Rare Isotopes, Lanzhou University, 222 Tianshui South Road, Lanzhou, 730000, China. Hauptthemen laut MEDLINE: Brachytherapy, Hydrogels. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Brachytherapy stands as an essential clinical approach for combating locally advanced tumors. Here, an injectable brachytherapy hydrogel is developed for the treatment of both local and metastatic tumor. Fe‐tannins nanoparticles are efficiently and stably radiolabeled with clinical used therapeutic radionuclides (such as 131 I, 90 Y, 177 Lu, and 225 Ac) without a chelator, and then chemically cross‐linked with 4‐armPEG‐SH to form brachytherapy hydrogel. Upon intratumoral administration, magnetic resonance imaging (MRI) signal from ferric ions embedded within the hydrogel directly correlates with the retention dosage of radionuclides, which can real‐time monitor radionuclides emitting short‐range rays in vivo without penetration limitation during brachytherapy. The hydrogel's design ensures the long‐term tumor retention of therapeutic radionuclides, leading to the effective eradication of local tumor. Furthermore, the radiolabeled hydrogel is integrated with an adjuvant to synergize with immune checkpoint blocking therapy, thereby activating potent anti‐tumor immune responses and inhibiting metastatic tumor growth. Therefore, this work presents an imageable brachytherapy hydrogel for real‐time monitoring therapeutic process, and expands the indications of brachytherapy from treatment of localized tumors to metastatic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Frontiers Science Center for Rare Isotopes, Lanzhou University, 222 Tianshui South Road, Lanzhou, 730000, China.
- School of Nuclear Science and Technology, Lanzhou University, 222 Tianshui South Road, Lanzhou, 730000, China.
- Department of Nuclear Medicine, Second Hospital of Lanzhou University, 82 Cuiying Gate, Lanzhou, 730000, China.
- Key Laboratory of Heavy Ion Radiation Medicine, Institute of Modern Physics, Chinese Academy of Sciences, 509 Nanchang Road, Lanzhou, 730000, China.
- School of Life Science and Engineering, Lanzhou University of Technology, 287 Langongping Road, Lanzhou, 730000, China.
- School of Stomatology, Lanzhou University, 199 Donggang West Road, Lanzhou, 730000, China.
ORCID-Profile: Bin Liu, Longlong Tian
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Lanzhou Youth Science and Technology Talent Innovation Project
- Science and Technology Program of Gansu Province
- National Key Research and Development Program of China
Zitieren
APA
Cui, Z., Wang, L., Liu, W., Xu, D., Zhang, T., Ma, B., Zhang, K., Yuan, L., Bing, Z., Liu, J., Liu, B., Wu, W., & Tian, L. (2024). Imageable Brachytherapy with Chelator‐Free Radiolabeling Hydrogel. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401438
Vancouver
Cui Z, Wang L, Liu W, Xu D, Zhang T, Ma B, et al. Imageable Brachytherapy with Chelator‐Free Radiolabeling Hydrogel. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401438
BibTeX
@article{Cui2024,
author = {Cui, Zhencun and Wang, Liqin and Liu, Wei and Xu, Dan and Zhang, Taofeng and Ma, Baoliang and Zhang, Kai and Yuan, Lingyan and Bing, Zhitong and Liu, Jiangyan and Liu, Bin and Wu, Wangsuo and Tian, Longlong},
title = {Imageable Brachytherapy with Chelator‐Free Radiolabeling Hydrogel},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401438}
}
EUVIMED